Beta Bionics Chief Product Officer Mensinger Mike sold 2,650 shares at $22 per share. The transaction represented about 1.5% of his prior holding, leaving him with 177,390 shares, giving investors the disclosed size of the sale and his remaining position.
Key Highlights
- Mensinger Mike sold 2,650 Beta Bionics shares.
- The sale price was $22 per share on 16 September 2026.
- Mensinger Mike owned 177,390 shares following the transaction.
Mensinger Mike, the company’s Chief Product Officer, sold 2,650 shares in the transaction. The disclosed price was $22 per share.
$22 Share Sale Completed on September 16
The transaction took place on 16 September 2026. The filing lists transaction code S. The sale covered 2,650 Beta Bionics (NASDAQ: BBNX) shares, with each share assigned a price of $22. Mensinger Mike was identified in the transaction as the company’s Chief Product Officer.
Post-Transaction Position Stood at 177,390 Shares
Following the transaction, Mensinger Mike’s reported position was 177,390 Beta Bionics shares. The sale amounted to about 1.5% of his prior shareholding. That percentage is stated against the position held before the transaction, while the 177,390-share figure describes the position afterward. The filing reports the 2,650-share sale and the 177,390-share post-transaction position. Transaction code S denotes an open-market or private sale.
FAQs
Q: How many Beta Bionics shares did Mensinger Mike sell?
A: Mensinger Mike sold 2,650 Beta Bionics shares. The transaction price was $22 per share, and the sale was classified with transaction code S.
Q: What was the price of Mensinger Mike’s Beta Bionics stock sale?
A: The Beta Bionics shares were sold at $22 per share. The article states that the sale covered 2,650 shares.
Q: How many Beta Bionics shares did Mensinger Mike own afterward?
A: Mensinger Mike owned 177,390 Beta Bionics shares after the transaction. The sale represented about 1.5% of his prior shareholding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.